Biography
Washington University (1992) Hematology/Oncology
Vanderbilt University (1989) Internal Medicine
Johannesburg Hospital Internal Medicine
University of Witwatersrand, Johannesberg, South Africa (1984)
Internal Medicine
Personal Statement
Dr. Rabinowitz has been a member of the UNM CRTC since 1997. He has been involved in many areas of work that include education, patient care, research and administration over the years. He has won awards, obtained grants, and published papers.
Areas of Specialty
Medical Oncologist: Blood, H&N, Lung, Neuro, GU
Internal Medicine
Hematology
Medical Oncology
Investigator initiated research
Multi-institutional trials
Education
Medical School: University of Witwatersrand, Johannesberg, South Africa (1984), Internal Medicine
Internship: Johannesburg Hospital, Internal Medicine
Residency: Vanderbilt University (1989), Internal Medicine
Fellowship: Washington University (1992), Hematology/Oncology
Certifications
Internal Medicine Hematology Medical Oncology
American Board of Internal Medicine, Medical Oncology (1997)
American Board of Internal Medicine, Hematology (1994)
American Board of Internal Medicine (1989)
Achievements & Awards
2016 Eisenberg Award from Cancer Services of New Mexico
2014 Outstanding Faculty Recipient School of Medicine 50th Anniversary
2012-13 NM Outstanding Educator
2011 People Living through Cancer Award
2011 Leonard Tow Humanism Award faculty recipient
2010-11 Robert Strickland Distinguished Service Award
1998-99 Deans Award of Distinction, University of New Mexico HSC
Gender
Male
Languages
- English
Courses Taught
Community Service
These out-each lecture were given to the community (who had been touched by some aspect of cancer or blood disorder)to give basic information about the topic
“I Can Cope “lecture on “Cancer and Chemotherapy” 4/99-4/05
Oncology community lecture “Therapeutic options for non-small cell lung cancer” 10/00
Medlecture.com internet lecture series “von Willebrand’s Disease” 2000
Oncology community lecture “Common cancers and recent advances in treatment” 9/01
Tumor Registry meeting “Leukemias and lymphomas, current treatment” 12/01
“Ask the Oncologist” retreat for Cancer Service New Mexico 9/02, 9/03, 9/04
Oncology community lecture “Cancer and patients”. Central United Methodist Church 12/02
“Leukemia and lymphoma” Cancer clinical trials series 6/03
“Recent advances in Breast Cancer Treatment” Nancy Floyd Haworth Memorial Breast Cancer Lectureship 9/03
“Recent Advances in Cancer” retreat for Cancer Service New Mexico 9/03
“Stem cells and cancer “ Oncology Community Lecture 2/04
“Death and Dying” invited lecture at the Funeral Consumers Alliance of Northern New Mexico 3/04
“Recent Advances in Cancer” retreat for Cancer Service New Mexico 9/04-9-22
“Ask the Oncologist” retreat for Cancer Service New Mexico 9/04-9-22
“CML:Beyond Imatinib” NMCCA 10/04
Panelist, Hispanic/Latina clinical Trial Conference, Albuquerque, NM 5/05
“Trials & Triumphs: Leukemia and Lymphoma” for the Leukemia & Lymphoma Society 4/06
Research and Scholarship
Full Member, Cancer Therapeutics Research Program,
UNM Comprehensive Cancer Center
I have published over 50 papers. Some have been laboratory based (1,2, 5), some translational (3.4), and some clinical (not shown).
1. Rabinowitz, I., Tuley, E.A., Mancuso, D.J., Randi, A.M., Firkin, B.G., Howard, M.A., Sadler, J. E. (1992) von Willebrand disease type B: A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein lb. Proc. Natl. Acad. Sci. (USA)89:9846-9849.2.
2. Rabinowitz, I., Randi, A.M., Shindler, K.S., Tuley, E.A., Rustagi, P.K., Sadler, J.E. (1993) Type II B mutation His (505) -> Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein lb. J. Biol. Chem. 268 (27) 20497-20501.
3. Davis LM, Harris C, Tang L, Doherty P, Hraber P, Sakai Y, Bocklage T, Doeden K, Hall B, Alsobrook J, Rabinowitz I, Williams TM, Hozier J (2007).Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma .J Mol Diagn; 9(3):327-36.
4. Jaetao J, Butler K, Adolphi N, Lovato D, Bryant H, Rabinowitz I, Winter S, Tessier T, Hathaway H, Bergemann C, Flynn E, Larson R (2009) Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles, Cancer Res.69(21):8310-6.
5. Shaheen MF, Tse JY, Sokol ES, Masterson M, Bansal P, Rabinowitz I, Tarleton CA, Dobroff AS, Smith TL, Bocklage TJ, Mannakee BK, Gutenkunst RN, Bischoff J, Ness SA, Riedlinger GM, Groisberg R, Pasqualini R, Ganesan S, Arap W. Genomic landscape of lymphatic malformations: a case series and response to the PI3K? inhibitor alpelisib in an N-of-1 clinical trial. Elife. 2022 Jul 5;11:e74510.